icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Pan-genotypic Hepatitis C Treatment With Glecaprevir+ Pibrentasvir Resulted in Improvement in Cardiovascular and Metabolic Extrahepatic Manifestations and Stable Renal Function: Results From Phase 3 Clinical Trials
 
 
  Reported by Jules Levin
AASLD - Presented at the American Association for The study of Liver Diseases (AASLD), October 20 -24, 2017, Washington DC, USA
 
Tram T. Tran,1 Darshan Mehta,2,3Federico J. Mensa,3Caroline Park,3Yuri Sanchez Gonzalez3 1Cedars-Sinai Medical Center, Los Angeles, California, United States; 2Schaeffer Center for Health Policy and Economics, University of Southern California, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States

1026171

1026172

1026173

1026174

1026175

1026176

1026177

1026178

1026179